Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

DexCom (DXCM)

NASDAQ: DXCM · Medical Devices · San Diego, CA

Our rating: Positive

Call changed from Neutral to Positive at $82.29, moderate conviction, October 30, 2026.

Breaks if: The positive call is broken if revenue growth decelerates to below 8% year-over-year in two consecutive quarterly reports within the next twelve months — at that pace, the 39.4x P/E multiple becomes difficult to defend and the core thesis of a durable, growing franchise loses its foundation. Separately, a 25% drawdown from the current price of $82.29 within twelve months, absent any parallel deterioration in reported fundamentals, would instead signal a market overreaction and prompt a reassessment toward the upside rather than the downside.

Key figures

Market value$29.6B
Revenue, last 12 months$5.1B
Net income, last 12 months$991M
Free cash flow, last 12 months$1.1B
Price to earnings29.9×
Free cash flow yield3.7%
Dividend yield0.0%
Operating margin24.0%
Return on equity37.7%
Beta to the S&P 5000.78
Volatility, annualized48.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.3B11.2%$0.72$273M
June 30, 2026$1.3B13.1%$0.64$185M
March 31, 2026$1.2B15.0%$0.51$449M
December 31, 2025$1.3B13.1%$0.67$192M
September 30, 2025$1.2B21.6%$0.70$579M
June 30, 2025$1.2B15.2%$0.45$209M
March 31, 2025$1.0B12.5%$0.27$97M
December 31, 2024$1.1B7.6%$0.38$177M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

17 ledger entries and 37 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.